New COVID Treatments Face FDA, Commercial Barriers Despite Ongoing Need
Executive Summary
Sponsors want more endpoint clarity as current state of government pandemic response, along with scientific and regulatory hurdles, is constraining efforts to refill a shrinking COVID medicine cabinet and could create vulnerabilities for future pandemics.